ST Yükselmeli Myokard Enfarktüsünde Çıplak Metal Stentler ve İlaç Kaplı Stentlerin Karşılaştırılması

Amaç: Bu çalışmada ST segment yükselmeli myokard enfarktüsünde ilaç kaplı stentleri ve çıplak metal stentleri karşılaştırmak istedik. Gereç ve Yöntem: Çalışmamıza merkezimize Ocak 2013 ve Mart 2016 tarihleri arasında başvuran toplam 1596 ST segment yükselmeli myokard enfarktüsü alındı. Katılımcılar çıplak metal stent grubu (n=1194) ve ilaç kaplı stent grubu (n=402) olarak iki gruba ayrıldı. Hastalar major kardiyak sonlanım acısından değerlendirildi. Bulgular: Gruplar arasında ilk 30 günde major kardiyak sonlanım ve tüm ölüm açısından fark olmamasına rağmen, toplam major kardiyak sonlanım insidansı (9,2% vs. 7,0%, p=0.02), stent thrombozu (4,2% vs. 2,6%, p=0.028) ve tekrar myokard enfarktüsü (6,9% vs. 4,8%, p=0.015) ilaç kaplı stent grubunda yüksek bulundu. Bununla birlikte toplam mortalitede, hedef damar ve lezyon revaskülarizasyonunda istatiksel anlamlı fark bulunmadı. Major kardiyak sonlanım ve toplam mortalite 2 yıllık takipte gruplar arasında benzer bulundu. Erkek cinsiyet (HR, 1.40; 95% CI, 1.00’den 1.94; p = 0.043) ve diyabet varlığı (HR, 1.73; 95% CI, 1.29’den 2.32; p

Drug Eluting Stents versus Bare Metal Stents in ST- Segment Elevation Myocardial Infarction

Objective: The aim of this study was to compare the effectiveness and safety of drug eluting stents (DES) with bare metal stents (BMS) in patients presented with ST- segment elevation myocardial infarction (STEMI) in a real world setting. Methods: One thousand five hundred ninety six STEMI patients treated with primary percutaneous coronary intervention from January 2013 to March 2016 were enrolled to study. One thousand one hundred ninety four of them received BMS while 402 of them received DES. Patients were analyzed for major adverse cardiac events (MACE) and stent thrombosis (ST).Results: There was no difference at 30 days in relation of MACE, all cause death, reMI, TVR, TLR and ST. The cumulative incidence of MACE was significantly higher in DES group (9,2% vs. 7,0%, p = 0.02) at 1 year. Stent thrombosis and re-MI incidence were significantly higher in DES group (4,2% vs. 2,6%, p = 0.028, 6,9% vs. 4,8%, p = 0.015) respectively at 1 year. There was no statistically significant difference in relation of all cause death, TVR and TLR at 1 year. The statistically differences between groups vanished at 2 year and the groups looked similar. Male gender (HR, 1.40; 95% CI, 1.00 to 1.94; p = 0.043) and presence of DM (HR, 1.73; 95% CI, 1.29 to 2.32; p

PDF

___

1. WijnsW, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThoracic Surgery (EACTS). European heart journal. 2010; 31(20): .2501-2555. https://doi.org/10.1093/eurheartj/ehq277.
2. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. International journal of cardiology. 2008;126(1):37-44. https://doi.org/10.1016/j.ijcard.2007.03.112
3. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC: cardiovascular interventions. 2011;4(1):14-23. DOI: 10.1016/j.jcin.2010.10.007
4. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet. 2011;377(9784):2193-204. https://doi.org/10.1016/S0140-6736(11)60764-2
5. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-51. doi: 10.1161/CIRCULATIONAHA.106.685313
6. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. New England Journal of Medicine. 1997;336(23):1621-8. DOI: 10.1056/NEJM199706053362301
7. Guo N, Maehara A, Mintz GS, et al. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation. 2010;122(11):1077-84. DOI:10.1161/CIRCULATIONAHA.109.906040
8. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. New England Journal of Medicine. 1999;341(26):1949-56. DOI: 10.1056/NEJM199912233412601
9. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. New England Journal of Medicine. 2002;346(13):957-66. DOI: 10.1056/NEJMoa013404
10. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. New England Journal of Medicine. 2006;355(11):1105-13. DOI: 10.1056/NEJMoa062598
11. Daemen J, Tanimoto S, García-García HM,et al. Comparison of three-year clinical outcome of sirolimus-and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). The American journal of cardiology. 2007;99(8):102732. https://doi.org/10.1016/j.amjcard.2006.11.070
12. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. International journal of cardiology. 2009;133(2):213-22. https://doi.org/10.1016/j.ijcard.2007.12.040
13. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. baremetal stents in patients with acute myocardial infarction. European heart journal. 2007;28(22):2706-13. https://doi.org/10.1093/eurheartj/ehm402
14. Pasceri V, Patti G, Speciale G, et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. American heart journal. 2007;153(5):749-54. https://doi.org/10.1016/j.ahj.2007.02.016
15. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. New England Journal of Medicine. 2009;360(19):1946-59. DOI: 10.1056/NEJMoa0810116
16. Kushner FG, Hand M, Smith SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2009;54(23):2205-41. DOI: 10.1016/j.jacc.2009.10.015
17. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. The Lancet. 2007;369(9562):667-78. https://doi.org/10.1016/S0140-6736(07)60314-6
18. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. The American journal of cardiology. 2006 ;98(3):352-6. https://doi.org/10.1016/j.amjcard.2006.02.039
19. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. New England Journal of Medicine. 2007;356(10):1030-9. DOI: 10.1056/NEJMoa067484
20. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. Jama. 2005;294(10):1215-23.
21. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Journal of the American College of Cardiology. 1999;33(3):634-9. DOI: 10.1016/S0735-1097(98)00635-4
22. Inoue T, Sohma R, Miyazaki T, et al. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. The American journal of cardiology. 2000;86(10):1057-62. https://doi.org/10.1016/S0002-9149(00)01159-0
23. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051-8. DOI:10.1161/CIRCULATIONAHA.106.675934
24. Rousan TA, Pappy RM, Chen AY, et al. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). The American journal of cardiology. 2014;114(8):1136-44. https://doi.org/10.1016/j.amjcard.2014.07.031

ISSN: 1309-3878
Yayın Aralığı: Yılda 3 Sayı
Başlangıç: 2009
Yayıncı: Düzce Üniversitesi Tıp Fakültesi Aile Hekimliği AD adına Yrd.Doç.Dr.Cemil Işık Sönmez